Shiba Inu (SHIB) has been a very traded coin within the memecoin market, where price action is highly dependent upon sentiment within the community and volatility of the markets. As SHIB holds speculative interest, its potential for growth becomes less dependent upon intrinsic utility and more so on overall market conditions. Mutuum Finance (MUTM), however, […]Shiba Inu (SHIB) has been a very traded coin within the memecoin market, where price action is highly dependent upon sentiment within the community and volatility of the markets. As SHIB holds speculative interest, its potential for growth becomes less dependent upon intrinsic utility and more so on overall market conditions. Mutuum Finance (MUTM), however, […]

Shiba Inu (SHIB) Price Forecast: Why SHIB and Mutuum Finance (MUTM) May Skyrocket in 2025

Shiba Inu (SHIB) has been a very traded coin within the memecoin market, where price action is highly dependent upon sentiment within the community and volatility of the markets. As SHIB holds speculative interest, its potential for growth becomes less dependent upon intrinsic utility and more so on overall market conditions.

Mutuum Finance (MUTM), however, is a $0.035 DeFi token building a lending-and-borrowing protocol geared towards long-term adoption. Unlike SHIB’s reliance on momentum, MUTM’s fundamentals render it a project that should realize more than average returns as buyers look for utility-driven tokens in 2025. Mutuum Finance might offer superior upside in the next bull cycle.

Shiba Inu (SHIB) Weakening Amid Tight Consolidation

Shiba Inu (SHIB) is trading at approximately $0.00001212. The token has been stagnant in a constricted range of $0.000012–$0.000013 for weeks, testing resistance at $0.0000130 without a strong break. In contrast, SHIB’s token burning rate has slowed significantly, casting doubts over deflation-driven growth stories, while whale accumulation is helping to some extent but is too weak to overcome broader volatility. 

Unless a catalyst comes along to push SHIB past its resistance levels, it will probably trade sideways or even drop to support at around $0.00001050. Analysts argue Mutuum Finance (MUTM) has more upside potential than SHIB.

Mutuum Finance Presale Success

Mutuum Finance is currently in presale phase 6 where 45% of it is sold out with the token available for sale at $0.035. The campaign has been going very fast and investors have raised more than $16.25 million up to this point. The project seeks to launch a USD-backed stablecoin on the Ethereum blockchain to lock up long-term value and easily get payback.

Mutuum Finance has developed a DeFi platform that is lender-friendly as well as borrower-friendly. It has P2P and P2C lending types. It is scalable and manipulation proof, and it can be accessed by retail investors or institutional investors.

Mutuum Finance (MUTM) also has strong risk controls, security-focused at all levels. The protocol is strong on under-collateralized and over-lending over-collateralization liquidation. Mutuum Finance does this through cascading Loan-to-Value ratios, liquidity, liquidation fees, and reserve factors hedging and insurance of platform liquidity in all states.

Interest charged by MUTM is variable and far lower than liquidity management. One of the applications in the market is lending with variable interest: surplus funds will start lending at subnormal rates of interest and liquidity deficit will charge extra to enable repayment of the loan and fresh deposits. It implies that the borrowers can have fixed rate borrowing in lending and at a preferred rate against the variable one and only for the highly liquid collateral.

Staking, buying tokens, and exchange listing are just a few of the long-term objectives of Mutuum Finance that lead to long-term expansion. It has a current  $100,000 giveaway and will award 10 participants $10,000 MUTM each.

Why MUTM’s Utility Trumps SHIB’s Hype in 2025

Mutuum Finance (MUTM) is picking up real steam while Shiba Inu (SHIB) struggles to break out of consolidation. SHIB is priced at $0.00001212, with limited catalysts for a large upside, while MUTM gives early investors an established utility-driven growth path. Stage 6 tokens are priced at $0.035, with the phase 45% sold out and over $16.25M raised. Backed by a USD-pegged stablecoin, dual P2P and P2C lending plans, and strict risk controls, MUTM is an efficient, secure DeFi platform. With a $100K contest and long-term aspirations like staking and exchange listings, MUTM has experts predicting outsized returns in the year 2025. Buy your Stage 6 tokens today before prices rise in the following phase.

For more information regarding Mutuum Finance (MUTM) please use the following links:

Website: https://mutuum.com/

Linktree: https://linktr.ee/mutuumfinance

Market Opportunity
BitShiba Logo
BitShiba Price(SHIBA)
$0.0000000004515
$0.0000000004515$0.0000000004515
-0.08%
USD
BitShiba (SHIBA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26